Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19214
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrice, Timothy J-
dc.contributor.authorThavaneswaran, Subotheni-
dc.contributor.authorBurge, Matthew-
dc.contributor.authorSegelov, Eva-
dc.contributor.authorHaller, Daniel G-
dc.contributor.authorPunt, Cornelis Ja-
dc.contributor.authorArnold, Dirk-
dc.contributor.authorKarapetis, Christos S-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorShapiro, Jeremy D-
dc.date.accessioned2018-09-13T00:21:12Z-
dc.date.available2018-09-13T00:21:12Z-
dc.date.issued2016-05-
dc.identifier.citationExpert review of anticancer therapy 2016; 16(5): 557-71-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19214-
dc.description.abstractThe treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice.-
dc.language.isoeng-
dc.subjectColorectal cancer-
dc.subjectConsensus-
dc.subjectRAS-
dc.subjectVEGF-
dc.subjectbiological-
dc.subjectchemotherapy-
dc.titleUpdate on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.-
dc.typeJournal Article-
dc.identifier.journaltitleExpert review of anticancer therapy-
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationAcademic Medical Center, University of Amsterdam, Amsterdam, The Netherlandsen
dc.identifier.affiliationCabrini Medical Centre, Monash University, Melbourne, Australiaen
dc.identifier.affiliationMedical Oncology, Royal North Shore Hospital, Sydney University, Sydney, Australiaen
dc.identifier.affiliationMedical Oncology, Royal Melbourne and Western Hospitals, Melbourne, Australiaen
dc.identifier.affiliationAbramson Cancer Centre, University of Pennsylvania, Philadelphia, USAen
dc.identifier.affiliationMedical Oncology, The Queen Elizabeth Hospital, Adelaide Colorectal Tumour Group and University of Adelaide, Adelaide, Australiaen
dc.identifier.affiliationMedical Oncology, Klinik für Tumorbiologie, Freiburg, Germanyen
dc.identifier.affiliationMedical Oncology, Flinders Medical Centre, Flinders University and Adelaide Colorectal Tumour Group, Adelaide, Australiaen
dc.identifier.affiliationSt Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, Australiaen
dc.identifier.affiliationMedical Oncology, Royal Brisbane Hospital, Brisbane, Australiaen
dc.identifier.affiliationMedical Oncology, University of Sydney and CTC, Sydney, Australiaen
dc.identifier.doi10.1586/14737140.2016.1170594-
dc.identifier.pubmedid27010906-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherTebbutt, Niall C
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Nov 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.